Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study.
3-day
COVID-19
early treatment
efficacy
remdesivir
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
18
02
2023
received:
10
01
2023
accepted:
02
03
2023
medline:
30
3
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
Recently, a benefit from administration of a 3-day course of early remdesivir (ER) in the outpatients' setting was reported. However, real-life data on its use is scarce. Therefore, we explored the ER clinical outcome in our outpatients' s cohort, compared to untreated controls. We included all patients who were prescribed ER from February to May 2022 and followed them up for 3 months and compared patients who received treatment with untreated controls. In the two groups the following outcomes were investigated: hospitalization and mortality rate, time of negativization and symptom's resolution, and postacute coronavirus disease 19 (COVID-19) syndrome prevalence. Overall, 681 patients were analyzed, mostly females (53.6%), and with a median age of 66 years (interquartile range: 54-77), 316 (46.4%) patients received ER, and 365 (53.6%) did not receive antiviral treatment (control group). Overall, 8.5% patients eventually required oxygen support, 8.7% were hospitalized for COVID-19, and 1.5% died. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization and ER (adjusted odds ratio [aOR]: 0.049 [0.015; 0.16], p < 0.001) independently reduced hospitalization risk. ER was significantly associated with a shorter duration of SARS-CoV-2 positivity at nasopharyngeal swabs (aβ -8.15 [-9.21; -7.09], p < 0.001) and of symptoms (aβ -5.11 [-5.82; -4.39], p < 0.001), and with lower rate of COVID-19 sequelae compared to control group (aOR: 0.18 [0.10; 0.31], p < 0.001). Even in the SARS-CoV-2 vaccination and Omicron era, in patients at high risk of developing severe disease, ER demonstrated to have a good safety profile and to significantly reduce the risk of disease progression and COVID-19 sequelae compared to untreated controls.
Substances chimiques
remdesivir
3QKI37EEHE
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28660Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Fisher D, Heymann D. Q&A: the novel coronavirus outbreak causing COVID-19. BMC Med. 2020;18(1):57.
Gralinski LE, Menachery VD. Return of the coronavirus: 2019-nCoV. Viruses. 2020;12(2):135.
Zeng H, Ma Y, Zhou Z, et al. Spectrum and clinical characteristics of symptomatic and asymptomatic coronavirus disease 2019 (COVID-19) with and without pneumonia. Front Med. 2021;8:645651.
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154.
Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-1839.
Myers LC, Liu VX. The COVID-19 pandemic strikes again and again and again. JAMA Network Open. 2022;5(3):e221760.
Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022: ciac724.
Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19. N Engl J Med. 2020;383(21):2041-2052.
Purwati B, Budiono BE, Rachman BE, et al. A randomized, double-blind, multicenter clinical study comparing the efficacy and safety of a drug combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for patients diagnosed with mild to moderate COVID-19 infections. Biochem Res Int. 2021;2021:6685921.
Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704.
Di Castelnuovo A, Costanzo S, Antinori A, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121(8):1054-1065.
Kojima Y, Nakakubo S, Kamada K, et al. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: a retrospective study. J Med Virol. 2022;94(12):5702-5712.
Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.
Trunfio M, Verga F, Ghisetti V, et al. Clinical phenotype and contagiousness of early breakthrough SARS-CoV-2 infections after BNT162b2 COVID-19 mRNA vaccine: a parallel cohort study in healthcare workers. Vaccines. 2021;9(12):1377.
Hu Y, Jo H, DeGrado WF, Wang J. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J Med Virol. 2022;94(5):2188-2200.
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048-1057.
Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209-221.
Mozaffari E, Chandak A, Zhang Z, et al. Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort. Clin Infect Dis. 2022;75(1):e450-e458.
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795-807.
Pizzorno A, Padey B, Julien T, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Reports Medicine. 2020;1(4):100059.
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827-1837.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813-1826.
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305-315.
Panagopoulos P, Petrakis V, Trypsianis G, Papazoglou D. Early 3-day course of remdesivir in vaccinated outpatients with SARS-CoV-2 infection. A success story. J Chemother. 2022;34(8):550-553.
Piccicacco N, Zeitler K, Ing A, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. J Antimicrob Chemother. 2022;77(10):2693-2700.
Qian G, Wang X, Patel NJ, et al. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. medRxiv. 2022.
Solera JT, Arbol BG, Bahinskaya I, Marks N, Humar A, Kumar D. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. Am J Transplant. 2023;23(1):78-83
Takahashi Y, Wakita H, Ishihara T, et al. Short-course remdesivir for healthcare-associated COVID-19: case series from a non-acute care hospital. J Infect Chemother. 2023;29(1):95-97.
Falcone M, Suardi LR, Tiseo G, et al. Early use of remdesivir and risk of disease progression in hospitalized patients with mild to moderate COVID-19. Clin Ther. 2022;44(3):364-373.
Spagnuolo V, Voarino M, Tonelli M, et al. Impact of remdesivir on SARS-CoV-2 clearance in a real-life setting: a matched-cohort study. DDDT. 2022;16:3645-3654.
Italian Drug Agency. Therapy with Remdesivir for adult patients with COVID-19. Update of January 12, 2022. https://www.aifa.gov.it/documents/20142/1123276/Remdesivir_update02_12.01.2022.pdf Accessed on November 30, 2022 Available at.
Mazzitelli M, Mengato D, Sasset L, et al. Molnupiravir and Nirmatrelvir/Ritonavir: tolerability, safety, and adherence in a retrospective cohort study. Viruses. 2023;15(2):384.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Med. 2021;27(4):601-615.
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441.
Montani D, Savale L, Noel N, et al. Post-acute COVID-19 syndrome. Eur Respir Rev. 2022;31(163):210185.
Zhao Y, Shang Y, Song W, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020;25:100463.
De Lorenzo R, Conte C, Lanzani C, et al. Residual clinical damage after COVID-19: a retrospective and prospective observational cohort study. PLoS One. 2020;15(10):e0239570.
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220-232.
Fernández-de-Las-Peñas C, Guijarro C, Plaza-Canteli S, Hernández-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 cough one year after SARS-CoV-2 infection: a multicenter study. Lung. 2021;199(3):249-253.
Mazzitelli M, Trunfio M, Sasset L, et al. Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA. Viruses. 2022;14(3):493.
Pierce JD, Shen Q, Cintron SA, Hiebert JB. Post-COVID-19 syndrome. Nurs Res. 2022;71(2):164-174.
Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 syndrome. incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378-383.
Trunfio M, Portesani F, Vicinanza S, et al. Real-life evidence of lower lung virulence in COVID-19 inpatients infected with SARS-CoV-2 omicron variant compared to wild-type and delta SARS-CoV-2 pneumonia. Lung. 2022;200(5):573-577.
Trunfio M, Richiardi L, Alladio F, et al. Determinants of SARS-CoV-2 contagiousness in household contacts of symptomatic adult index cases. Front Microbiol. 2022;13:829393.
Trunfio M, Calcagno A, Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. Lancet Infect Dis. 2021;21(7):914-915.